IDH1 and central nervous system cancer: 23 patients with a range of tumour types (i.e., glioma IDH-mutant (G-mut, n=4 with 13 samples), glioma-IDH wild type (G-WT, n=7), metastatic lung cancer (LM, n=7) and metastatic breast cancer (BM, n=5)) vs 8 control patients (NT)